Comparative Pharmacology
Head-to-head clinical analysis: MICONAZOLE NITRATE versus MYIDYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICONAZOLE NITRATE versus MYIDYL.
MICONAZOLE NITRATE vs MYIDYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal CYP450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
c-Met/ALK inhibitor; inhibits receptor tyrosine kinases MET and ALK, blocking downstream signaling pathways including PI3K/AKT and RAS/RAF/MEK/ERK, leading to reduced tumor cell proliferation and angiogenesis.
Topical: Apply twice daily for 2-4 weeks. Vaginal: 200 mg suppository at bedtime for 3 days, or 100 mg suppository at bedtime for 7 days, or 1200 mg suppository as a single dose. Oral (buccal): 50 mg once daily for 14 days.
50 mg orally twice daily without regard to meals.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 20-40 hours) following intravenous administration. This extended half-life supports twice-daily dosing for systemic infections.
Terminal elimination half-life is approximately 12 hours (range 10–14 hours) in adults with normal renal function; prolonged in renal impairment (up to 24–30 hours).
Miconazole is primarily metabolized in the liver, with less than 1% of an intravenous dose excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 50% of the dose as metabolites. Renal elimination of metabolites is minimal.
Primarily renal excretion as unchanged drug (~60%) and metabolites (~30%); biliary/fecal excretion accounts for ~10%.
Category A/B
Category C
Antifungal
Antifungal